Antibodies can be programmed to bind cancer cells using covalently binding antigens and adapters.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Popkov, M., Gonzalez, B., Sinha, S.C. & Barbas, C.F. III. Proc. Natl. Acad. Sci. USA 106, 4378–4383 (2009).
Rader, C. et al. Proc. Natl. Acad. Sci. USA 100, 5396–5400 (2003).
Li, L.-S. et al. J. Med. Chem. 47, 5630–5640 (2004).
Guo, F. et al. Proc. Natl. Acad. Sci. USA 103, 11009–11014 (2006).
Popkov, M. et al. Int. J. Cancer 119, 1194–1207 (2006).
Doppalapudi, V.R. et al. Bioorg. Med. Chem. Lett. 17, 501–506 (2007).
Lu, Y. & Low, P.S. Cancer Immunol. Immunother. 51, 153–162 (2002).
Shokat, K.M. & Schultz, P.G. J. Am. Chem. Soc. 113, 1861–1862 (1991).
Mullis, K.B. Chemically programmable immunity. US patent 7,422,746 (2008).
Bertozzi, C.R. & Bednarski, M.D. J. Am. Chem. Soc. 114, 5543–5546 (1992).
Naicker, K.P. et al. Org. Biomol. Chem. 2, 660–664 (2004).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Meares, C. Targeted instant immunity. Nat Biotechnol 27, 452–453 (2009). https://doi.org/10.1038/nbt0509-452
Issue Date:
DOI: https://doi.org/10.1038/nbt0509-452